
==== Front
Case Rep Hematol
Case Rep Hematol
CRIHEM
Case Reports in Hematology
2090-6560
2090-6579
Wiley

10.1155/2024/4303614
Case Report
Acute Coronary Syndrome as an Unusual Initial Presentation of T-Prolymphocytic Leukemia: A Case Report and Review of the Literature
https://orcid.org/0009-0006-1306-7775
Klein Christian R. christian.klein@ukbonn.de
1 2
https://orcid.org/0000-0001-6962-5330
Jansen Felix 3
https://orcid.org/0009-0002-9324-5527
Brossart Peter 1 2
https://orcid.org/0000-0001-7473-7476
Herling Marco 4
https://orcid.org/0000-0002-3748-2184
Feldmann Georg 1 2
1 Department of Oncology, Hematology, Immune-Oncology and Rheumatology University Hospital Bonn, Bonn, Germany
2 Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD), Bonn, Germany
3 Department of Internal Medicine II University Hospital Bonn University of Bonn, Venusberg-Campus 1, Bonn 53127, Germany
4 Department of Hematology, Cellular Therapy, and Hemostaseology University of Leipzig, Leipzig, Germany
Academic Editor: Håkon Reikvam

2024
27 8 2024
2024 430361422 4 2024
29 7 2024
Copyright © 2024 Christian R. Klein et al.
2024
https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
T-prolymphocytic leukaemia (T-PLL) is the most common mature T-cell leukaemia in Central Europe and is often manifested by rapidly increasing lymphocytosis, marked bone marrow infiltration and splenomegaly. In 10–15% of cases, the diagnosis is made by incidental findings in otherwise asymptomatic patients. Here we report a case of T-PLL that initially became symptomatic due to the presence of acute coronary syndrome (ACS). Initially, emergency coronary angiography with consecutive emergency 5-coronary artery bypass grafting (CABG) was performed. Leukocytosis was found perioperatively and T-PLL (with TCL1 rearrangement) was subsequently diagnosed. Despite known potential cardiotoxicity, the patient was treated with the anti-CD52 antibody alemtuzumab with a gradual dose increase from 3 mg to 30 mg per day. Systemic alemtuzumab therapy resulted in the complete remission of T-PLL in the bone marrow without any impairment to cardiac function. The patient was then eligible to undergo a consolidating allogeneic stem cell transplant (alloSCT). The reported case shows that T-PLL can also become initially symptomatic through an acute coronary syndrome on the basis of complex coronary heart disease. Targeted antileukaemic therapy with the monoclonal antibody alemzutumab can lead to effective systemic cytoreduction without cardiac dysfunction even in patients with severe cardiac disease, although cases of cardiotoxicity have been reported.
==== Body
pmc1. Background

T-prolymphocytic leukaemia (T-PLL) is the most common mature T-cell leukaemia in Central Europe with an incidence of ≈2.0/million. It often presents with rapidly increasing lymphocytosis, marked bone marrow infiltration, and splenomegaly [1]. In approximately 10–15% of cases, the diagnosis is an incidental finding in otherwise asymptomatic patients. Current pathogenetic disease concepts include constitutive activation of T-cell leukaemia 1 (TCL1) oncogenes due to defective rearrangements with T-cell receptor (TCR) genes in combination with deleterious ATM aberrations [2]. The neoplastic cells present as mature, postthymically differentiated lymphocytes and usually carry a memory phenotype [3]. Given the very low incidence of T-PLL and the limited data sets of documented cases, no exogenous risk factors have yet been identified. T-PLL is also not a typical secondary neoplasia after cytostatic or immunomodulatory therapy. Medium age at first diagnosis is approximately 65 years, increased incidence rates have been described in younger patients with autosomal recessive ataxia telangiectasia (Louis–Bar syndrome), which represent compound heterozygous individuals for biallelic inactivating mutations of the ATM tumor suppressor gene [4, 5].

Clinically, T-PLL often presents with nonspecific symptoms such as fatigue, infections, bleedings, and B-symptoms in the context of a marked lymphocytosis, which in 75% of patients is found to exceed 100,000/μl and often increases at an exponential rate [6]. Bone marrow infiltration or splenomegaly is observed in approximately 80% of cases. Frequent further findings include small-node generalized lymphadenopathies (45–50%), thrombocytopenias (<100,000/μl in 45–50%), hepatomegaly (35–40%), anemias (<10 g/dL in 25%), skin infiltrations (25%), and malignant effusions (10–15%; pleura, pericardium, ascites) [7]. Established major diagnostic criteria are blood monoclonal lymphocytosis (>5 × 103/μl) of mature T-cell immunophenotype and evidence of a chromosomal aberration involving the loci 14q32.1 (TCL1A) or Xq28 (MTCP1) or evidence of T-cell-specific expression of TCL1A or MTCP1 protein by flow cytometry or immunohistochemistry. Secondary criteria include rapidly increasing blood lymphocyte counts with doubling times <6 months, additional evidence of chromosomal aberrations with gains on 8q, del11q22, or complex aberrant karyotype, the presence of effusions or (hepato)splenomegaly, or prolymphocytic morphology on blood smear [6, 8].

Due to its high efficacy, intravenous therapy with the anti-CD52 antibody alemtuzumab is a currently widely accepted first-line therapeutic standard [1]. The only curative treatment option to date is subsequent allogeneic stem cell transplantation (alloSCT), in which 15–30% of patients achieve remission that lasts longer than 4-5 years. Due to the high one-year mortality after alloSCT and with only 30–50% of patients being eligible for it, median overall survival across all patients is <2 years, and the 5-year survival rate is <5% [9].

Here, we report a case of T-PLL who initially became symptomatic with acute coronary syndrome (ACS) due to high-grade coronary three-vessel disease. Following coronary artery bypass grafting (CABG), in which five grafts were employed to treat triple vessel disease, antileukaemic therapy with alemtuzumab led to effective systemic cytoreduction without cardiac dysfunction although cases of cardiotoxicity have been reported. The case shows ACS as an unusual first symptom of T-PLL and demonstrates that alemtuzumab therapy (in an adapted, steady dose increase) can also be an effective induction therapy before alloSCT in patients with severe cardiac disease.

2. Case Presentation

A 66-year-old male patient presented at the emergency department of a peripheral hospital in February 2021 with suspected subacute myocardial infarction and angina pectoris symptoms that had persisted for one week. The patient had no known cardiovascular risk factors. Due to ST-segment depressions in II, III, aVF, and V2-V6 of the 12-channel ECG, immediate coronary angiography was performed. It revealed severe coronary triple-artery disease and the patient were transferred to cardiac surgery for emergency myocardial revascularization. A 5-fold CABG (LIMA ad LAD, V ad PDA, V ad M1 (first marginal branch of the circumflex ramus), V and D1, V as T-graft ad M1 and LAD; description in the list of abbreviations) was performed under hypothermic extracorporeal circulation. Intraoperatively, a markedly enlarged heart with hypokinesis of the posterior wall was seen with preserved pump function without arteriosclerosis of the ascending aorta. Given the calcification of the left anterior descending artery (LAD) throughout its length, along with the limited explorability of only approximately 1.5 cm proximally and in the distal third, a LIMA-LAD bypass and a venous T-graft at M1 and LAD were deemed the most appropriate options. Flow measurement of the grafts showed acceptable flows to the target vessels (LIMA-LAD: 80 ml/min, V-LAD: 60 ml/min, M1: 60 ml/min, D1 26 ml/min, PDA: 80 ml/min) so that surgery could be finalized without transfusion of blood products. Apart from a paranasal basal cell carcinoma, excised in 2020, no other previous diseases were present. Clinically, there were no signs of infection, no fever, no pain, and no signs of bleeding. No B-symptoms were detected, although slight night sweats had occurred in the days following the operation. The patient had not taken any long-term medication prior to his hospitalisation. There were no indications of malignant diseases in the family, the patient's mother had suffered a myocardial infarction. The patient was a nonsmoker and only occasionally consumed a small amount of alcohol. He had worked as an engineer in a chemical company before his retirement and had no occupational exposure to potentially toxic substances. The emergency situation described occurred acutely without a previous cardiological medical history and without previous cardiological events.

The initial blood count in the emergency department showed haemoglobin 14.1 g/dl, 30.60 G/l leucocytes, 151 G/l platelets, 14.08 G/l lymphocytes, 0.92 G/l monocytes, 9.79 G/l segmental nucleated neutrophils, 0.31 G/l basophils, and 0.31 G/l eosinophils.

On the first postoperative day, perioperative antibiotic treatment with cefuroxime (parenteral 1500 mg/100 ml i.v. over 24 h) resulted in a leucocytosis of 41.7 G/l and a subfebrile temperature of 36.9°C. There was no serological evidence of an acute viral infection (hepatitis B, C, HIV) or reactivation (CMV, EBV, and HSV).

Contrast-enhanced computed tomography (CT, neck/thorax/abdomen, Figure 1) showed increased, partially enlarged lymph nodes, bilaterally cervical, axillary, retroperitoneal/paraaortic, and inguinal, as well as a slightly plump, discretely enlarged spleen (pole-to-pole 11.5 cm) with homogeneous parenchyma. There was no evidence of pericardial effusion on imaging.

Due to the increasing leukocytosis, treatment with prednisolone and vincristine was initiated before the diagnosis was completed under the suspected diagnosis of acute lymphoblastic T-cell leukaemia (T-ALL), which was well tolerated by the patient.

Cardiac involvement was suspected by cardiac magnetic resonance imaging (MRI), which revealed a postischaemic scar of the left ventricular posterior wall (more than 75% transmural) and a normally sized left ventricle with significantly reduced left ventricular function (LVEDV/BSA: 85 ml/m2, LVEF: 38%) without higher-grade valvular vitiation (Figure 2).

By flow cytometry and cytogenetics, the diagnosis of T-PLL could be established with a main criterion of mature T-cell immunophenotype and a secondary criterion of chromosomal aberration with an increase to 8q in 03/21. The cytomorphology characteristic of T-PLL is shown as an example in Figures 3 and 4. With stable leukocyte counts after prednisolone and vincristine, a temporary watch and wait approach was adopted until final diagnosis confirmation and cardiological rehabilitation. A cardiological follow-up examination in 05/21 revealed preserved left ventricular function on echocardiography with an ejection fraction (EF) of 57.1% without higher-grade vitiation, pericardial effusion, and clinically without cardiac symptoms.

In 06/21, the diagnosis of T-PLL (stage IV Ann Arbor) was finally confirmed by detection of TCL1a rearrangement in peripheral blood lymphocytes using FISH. CT-based staging showed a discrete increase in the size of the cervical, axillary, abdominal and inguinal lymph nodes as well as increasing splenomegaly.

After a continuous increase in the leucocyte count to 90 G/l at the end of 06/21 (Figure 5), the patient received cytoreductive therapy with cyclophosphamide/dexamethasone (200 mg/12 mg absolute/day) for five days. The reasoning underlying this preinduction phase was to minimise the potential cardiac risks described for alemtuzumab. This prephase of therapy was tolerated without complications. Alemtuzumab was then administered intravenously in steadily increasing doses (doses d1: 3 mg, d3: 10 mg, d5: 30 mg). After the first two doses, there was a progressive increase in serum creatinine (presumably in connection with tumour lysis), which rapidly subsided under supportive treatment. On day 5, administration of the 30 mg dose resulted in an anaphylactic reaction with chills, fever, drop in blood pressure, and severe nausea, which was effectively controlled by treatment with H1 and H2 blockers and glucocorticoids. A further dose of 30 mg was well tolerated with extended premedication with dexamethasone 40 mg, so that premedication with dexamethasone was continued for the next doses.

With continued good tolerability, the therapy was continued on an outpatient basis in 07/21. During treatment in 07/21 and 08/21, CMV reactivation occurred (specific nucleic acid amplificates: 3,640 IU/ml), which was treated with valganciclovir (900 mg bid) as an outpatient, as well as fungal pneumonia, which was treated as an inpatient with liposomal amphotericin B and piperacillin/tazobactam (consecutive switch to meropenem). A new bone marrow biopsy was performed in 08/21, which revealed a hypoplastic bone marrow with cytological complete remission of T-PLL. At the time of completion of this case report, the patient was in a good general condition and was able to continue the planned therapy with alemtuzumab until the consecutive consolidative alloSCT (MUD-PBSCT, conditioning: fludarabine 30 mg/m^2 KOF and TBI) in 11/21. A follow-up echocardiogram in 02/22 showed a largely preserved left ventricular function with an ejection fraction (EF) of 49% without higher-grade ventricular ejection, electrocardiography showed a normo-frequent sinus rhythm without specific pathologies.

3. Discussion

The case presented here is noteworthy due to ACS as the first symptom of T-PLL and alemtuzumab therapy in the presence of severe underlying cardiological disease.

3.1. ACS as Initial Symptom of T-PLL

ACS as first symptom of T-PLL is highly uncommon. To our knowledge, this is the first case report of ACS as an initial symptom of T-PLL. In other types of leukaemia, ACS has been described as the first clinical symptom in some case reports [9–20]. Some case reports have also reported T-PLL with cardiac involvement [21–24]. Case reports to date also describe any degree of cardiac symptoms up to and including cardiac arrest as the initial symptom of cardiac infiltration [18]. Furthermore, several case reports have documented the occurrence of pericardial and myocardial leukaemia infiltration in instances of ALL recurrence subsequent to alloSCT [25–27]. The main pathomechanisms underlying ACS in the more common acute and chronic leukaemias are myocardial ischaemia due to anaemia, rheological disturbances due to leukostasis associated with hyperleukocytosis and hypercoagulable states [28]. A systematic review of case reports with cardiac infiltration as the first symptom in acute lymphoblastic leukaemia can be found in [29]. In the case presented here, global clotting times were in the normal range, leukocytosis was only moderate (30,000/μl), and the haemoglobin level was 14.1 mg/dl. The ACS developed on the basis of a complex three-vessel disease with moderate leukocytosis and increasing kinetics. The case presented here demonstrates that in the presence of coronary artery disease, ACS can occur in the manifestation of leukaemia even with only moderate leukocytosis. In this sense, a previous cardiological or angiological disease may lower the leukocyte threshold for a leukostasis syndrome. For this reason, it may make sense to initiate cytoreductive therapy early in the diagnosis of leukaemia in the presence of a positive cardiological history and, on the other hand, to include an underlying haematological disease in the differential diagnosis of ACS, even in the presence of only moderate leukocytosis, as in the case presented here.

The neutrophil to lymphocyte ratio (NLR) has proven to be a useful predictive marker for identifying high-risk ACS patients with a poor prognosis [30, 31]. It should be noted that patients with malignant haematological diseases as the underlying cause of acute cardiac symptoms may represent an exception to this rule, and that NLR may not be a suitable biomarker in such cases [32, 33].

3.2. Alemtuzumab in Patients with Severe Preexisting Cardiological Disease

Alemtuzumab is a humanised IgG1κ monoclonal antibody that binds specifically to the CD52 glycoprotein (CAMPATH 1 antigen), which is expressed on mature B and T lymphocytes. The antibody is used in the treatment of multiple sclerosis, chronic lymphocytic leukaemia (CLL), T-PLL, and for induction therapy in kidney transplantation [34]. Cardiotoxicity of alemtuzumab has been described in several case reports [35–38]. In the TPLL1 study [39], there was also one documented death due to myocardial infarction, which was presumably attributable to the cardiotoxicity of alemtuzumab. In the case presented here, the T-PLL initially presented as ACS in the setting of severe coronary artery disease. Despite a risk of further cardiac events, early cytoreduction with cyclophosphamide/dexamethasone prior to definitive alemtuzumab induction proved successful, as it was tolerated without complications and may have reduced cardiac risk. In addition to reducing the overall leukaemic burden and thus alemtuzumab-induced cytokine release, it is also known that cyclophosphamide positively modulates the local macrophage milieu towards alemtuzumab sensitisation [40]. The approach described here may therefore also serve as a guide for the treatment of similar future cases of T-PLL with severe preexisting cardiac disease.

Acknowledgments

The authors thank the patient on whom this case report is based, whose medical history was the starting point and inspiration for this work.

Abbreviations

ACS: Acute coronary syndrome

alloSCT: Allogeneic stem cell transplantation

BSA: Body surface area

CABG: Coronary artery bypass grafting

CLL: Chronic lymphatic leukaemia

CT: Computed tomography

ECG: Electrocardiogram

EF: Ejection fraction

FISH: Fluorescence in situ hybridization

LAD: Left anterior descending artery

LIMA: Left internal mammary artery

LVEDV: Left ventricular end-diastolic volume

LVEF: Left ventricular ejection fraction

M1: First marginal branch of the circumflex ramus

MRI: Magnetic resonance imaging

NLR: Neutrophil to lymphocyte ratio

PDA: Posterior descending artery

PET-CT: Positron emission tomography-computed tomography

T-ALL: T-cell acute lymphoblastic leukaemia

TCL1: T-cell leukaemia 1

TCR: T-cell receptor

T-PLL: T-prolymphocytic leukaemia

TTE: Transthoracic echocardiogram.

Data Availability

No data were used to support this study.

Ethical Approval

This case report is a completely retrospective research project, as all the data to be used were already available at the time the research question was posed. According to § 15 paragraph 1 of the professional code of conduct of the Ärztekammer Nordrhein, retrospective epidemiological research projects are exempt from the obligation to seek the advice of a Medical Ethics Committee. The Ethics Committee of the Medical Faculty of Bonn agrees with this provision, so that ethical approval is not required for this study according to local guidelines. All data were anonymised in accordance with EU Regulation 2016/679 (General Data Protection Regulation). Clinical treatment and data collection were conducted in accordance with the Declaration of Helsinki.

Consent

Written informed consent was obtained from the patient for publication of the details of their medical case and any accompanying images.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

Authors' Contributions

C.K. and G.F. intiated the idea and concept of this study. G.F. clinically supervised the study. C.K. wrote the original draft. C.K., G.F., M.H., F.J., and P.B. reviewed and edited the article.

Figure 1 Exemplary transverse section of the staging CT image at initial diagnosis: the number of thoracic lymph nodes is clearly increased.

Figure 2 Cardiac MRI imaging at initial diagnosis after cardiovascular bypass surgery: infarct scar (over 75% transmural) on the left ventricular posterior wall and a normally dimensioned left ventricle with significantly reduced left ventricular function.

Figure 3 Cytomorphological findings in peripheral blood at initial diagnosis (magnification 100x): blood smear showing aberrant lymphoid cells with partially scored nuclei, including prominent nucleoli, and deep basophilic cytoplasm with multiple small protrusions (blebs) consistent with T-PLL.

Figure 4 Findings in bone marrow at initial diagnosis (magnification 100x): prominent infiltration (approx. 70% of nucleated cells) by atypical small T-cells with prolymphocytic morphology. Lymphoid-appearing cells with mostly mature nuclear chromatin and slightly enlarged and shape-variable nuclei. In addition, repressed myelopoiesis with slightly increased eosinophilic granulocytes.

Figure 5 Kinetics of leukocytes in peripheral blood (G/l, measured by flow cytometry, reference range 3.6–10.5 G/l) over time (days) since emergency presentation with ACS.
==== Refs
1 Braun T. von Jan J. Wahnschaffe L. Herling M. Advances and perspectives in the treatment of T-PLL Current Hematologic Malignancy Reports 2020 15 2 113 124 10.1007/s11899-020-00566-5 32034661
2 Schrader A. Crispatzu G. Oberbeck S. Actionable perturbations of damage responses by TCL1/ATM and epigenetic lesions form the basis of T-PLL Nature Communications 2018 9 1 p. 697 10.1038/s41467-017-02688-6 2-s2.0-85042274833
3 Oberbeck S. Schrader A. Warner K. Noncanonical effector functions of the T-memory–like T-PLL cell are shaped by cooperative TCL1A and TCR signaling Blood 2020 136 24 2786 2802 10.1182/blood.2019003348 33301031
4 Taylor A. Metcalfe J. Thick J. Mak Y. Leukemia and lymphoma in ataxia telangiectasia Blood 1996 87 2 423 438 10.1182/blood.V87.2.423.bloodjournal872423 8555463
5 Suarez F. Mahlaoui N. Canioni D. Incidence, presentation, and prognosis of malignancies in ataxia-telangiectasia: a report from the French national registry of primary immune deficiencies Journal of Clinical Oncology 2015 33 2 202 208 10.1200/JCO.2014.56.5101 2-s2.0-84920983463 25488969
6 Herling M. Khoury J. D. Washington L. T. Duvic M. Keating M. J. Jones D. A systematic approach to diagnosis of mature T-cell leukemias reveals heterogeneity among WHO categories Blood 2004 104 2 328 335 10.1182/blood-2004-01-0002 2-s2.0-3142523199 15044256
7 Jain P. Aoki E. Keating M. Characteristics, outcomes, prognostic factors and treatment of patients with T-cell prolymphocytic leukemia (T-PLL) Annals of Oncology 2017 28 7 1554 1559 10.1093/annonc/mdx163 2-s2.0-85041248150 28379307
8 Staber P. B. Herling M. Bellido M. Consensus criteria for diagnosis, staging, and treatment response assessment of T-cell prolymphocytic leukemia Blood 2019 134 14 1132 1143 10.1182/blood.2019000402 2-s2.0-85072944454 31292114
9 Krishnan B. Else M. Tjonnfjord G. E. Stem cell transplantation after alemtuzumab in T‐cell prolymphocytic leukaemia results in longer survival than after alemtuzumab alone: a multicentre retrospective study British Journal of Haematology 2010 149 6 907 910 10.1111/j.1365-2141.2010.08134.x 2-s2.0-77952676880 20201944
10 Altwegg S. C. Altwegg L. A. Maier W. Intracoronary thrombus with tissue factor expression heralding acute promyelocytic leukaemia European Heart Journal 2007 28 22 p. 2731 10.1093/eurheartj/ehm216 2-s2.0-36248987130
11 Cahill T. J. Chowdhury O. Myerson S. G. Myocardial infarction with intracardiac thrombosis as the presentation of acute promyelocytic leukemia: diagnosis and follow-up by cardiac magnetic resonance imaging Circulation 2011 123 10 e370 e372 10.1161/CIRCULATIONAHA.110.986208 2-s2.0-79953049854 21403118
12 Cohen Y. Amir G. Da’as N. Gillis S. Rund D. Polliack A. Acute myocardial infarction as the presenting symptom of acute myeloblastic leukemia with extreme hyperleukocytosis American Journal of Hematology 2002 71 1 47 49 10.1002/ajh.10155 2-s2.0-0036733575 12221675
13 Jao G. T. Knovich M. A. Savage R. W. Sane D. C. ST-elevation myocardial infarction and myelodysplastic syndrome with acute myeloid leukemia transformation Texas Heart Institute Journal 2014 41 2 234 237 10.14503/THIJ-12-2905 2-s2.0-84898901462 24808792
14 Manogna D. Sham R. Acute myocardial infarction as initial manifestation of acute myeloid leukemia: a rare manifestation of leukostasis Cureus 2020 12 8 e9551 10.7759/cureus.9551
15 Odani K. Abe J. Tsuyuki Y. Acute coronary syndrome in acute myeloid leukemia with maturation accompanying megakaryocytic differentiation Case Reports in Pathology 2020 2020 1 7 10.1155/2020/8886298
16 Muñiz A. E. Myocardial infarction and stroke as the presenting symptoms of acute myeloid leukemia Journal of Emergency Medicine 2012 42 6 651 654 10.1016/j.jemermed.2009.04.061 2-s2.0-84862222444 19500934
17 Kotla S. Leukocytosis: a risk factor for myocardial infarction Research Reports in Clinical Cardiology 2012 23 27 10.2147/RRCC.S30023
18 Torosyan N. Gonzalez Mancera M. S. Tourtellotte W. G. Kedan I. Leukemic infiltration of myocardium presenting as cardiac arrest Journal of the American College of Cardiology: Case Reports 2021 3 6 922 927 10.1016/j.jaccas.2021.01.033 34317656
19 Ma T. Xing H. Zhu X. Massive pericardial effusion and pleural effusion: cardiac and pleural infiltration in newly diagnosed acute myeloid leukemia Journal of the Egyptian National Cancer Institute 2021 33 1 p. 23 10.1186/s43046-021-00081-5
20 Lima Da Silva G. Valle S. Pinto F. J. Almeida A. G. Leukaemic myocardial infiltration presenting as acute heart failure European Heart Journal - Cardiovascular Imaging 2015 16 4 p. 460 10.1093/ehjci/jeu301 2-s2.0-84942089078
21 Arranto C. Tzankov A. Broken heart by T-prolymphocytic leukemia Blood 2017 130 5 p. 691 10.1182/blood-2017-05-784363 2-s2.0-85026730405
22 Cheng H. Feldman T. Butt Y. T-cell prolymphocytic leukemia with extensive cardiovascular involvement and a rare TCR gene rearrangement Case Rep Hematol 2018 2018 1 8 10.1155/2018/2630130
23 Bonanni L. Adami F. Angelini A. Right atrial mass in a patient with T-cell chronic lymphocytic leukemia: an unusual mechanism of thrombus formation Circulation 2007 116 25 e333 e334 10.1161/CIRCULATIONAHA.107.713008 2-s2.0-37349023640
24 Seko Y. Azuma M. Yagita H. Perforin-positive leukemic cell infiltration in the heart of a patient with T-cell prolymphocytic leukemia Internal Medicine 1995 34 8 782 784 10.2169/internalmedicine.34.782 2-s2.0-0029349046 8563121
25 Yuan J. Zhang Y. Zhou H. Wang S. Liu Q. Gao Y. Radiotherapy in Philadelphia chromosome-positive acute lymphoblastic leukemia with pericardial invasion after transplantation: a case report Oncology Letters 2023 26 3 p. 415 10.3892/ol.2023.14001 37600325
26 Chang K. Kim D.-Y. Lee K.-H. An isolated cardiac relapse after allogeneic hematopoietic stem cell transplantation for acute lymphoblastic leukemia Korean Journal of Internal Medicine (English Edition) 2017 32 4 753 757 10.3904/kjim.2015.115 2-s2.0-85025163069
27 Facenda-Lorenzo M. Sánchez-Quintana A. Quijada-Fumero A. Cardiac relapse of acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation Case Reports in Oncological Medicine 2016 2016 1 5 10.1155/2016/5091021 2-s2.0-85043547010
28 Benedek I. Lázár E. Sándor-Kéri J. Bíró S. Jakab S. Benedek I. Acute coronary syndromes in patients with hematological disorders Journal Of Cardiovascular Emergencies 2016 2 4 159 168 10.1515/jce-2016-0024
29 Luo Z. Cheng J. Wang Y. Cardiac infiltration as the first manifestation of acute lymphoblastic leukemia: a systematic review Frontiers Oncology 2022 12 805981 10.3389/fonc.2022.805981
30 Song M. Graubard B. I. Rabkin C. S. Engels E. A. Neutrophil-to-Lymphocyte ratio and mortality in the United States general population Scientific Reports 2021 11 1 p. 464 10.1038/s41598-020-79431-7 33431958
31 Zhao Y. Zhang S. Yi Y. Neutrophil-to-Lymphocyte ratio as a predictor for cardiovascular diseases: a cohort study in tianjin, China Journal of Human Hypertension 2022 37 7 576 583 10.1038/s41371-022-00724-7 35859165
32 Sharma D. J. Nath H. J. Batta A. Goala A. K. Neutrophil-to-Lymphocyte ratio (NLR) useful as a cost-effective preliminary prognostic marker in ST-elevation myocardial infarction (STEMI): an observational study from a tertiary care hospital in northeast India Cureus 2023 15 3 e36885 10.7759/cureus.36885
33 Banahene N. O. Sinha T. Shaikh S. Effect of elevated neutrophil-to-lymphocyte ratio on adverse outcomes in patients with myocardial infarction: a systematic review and meta-analysis Cureus 2024 16 6 e61647 10.7759/cureus.61647
34 Hanaway M. J. Woodle E. S. Mulgaonkar S. Alemtuzumab induction in renal transplantation New England Journal of Medicine 2011 364 20 1909 1919 10.1056/nejmoa1009546 2-s2.0-79956189911 21591943
35 Basquiera A. L. Berretta A. R. García J. J. Palazzo E. D. Trippi F. Guaschino R. Coronary ischemia related to alemtuzumab therapy Annals of Oncology 2004 15 3 539 540 10.1093/annonc/mdh114 2-s2.0-1842607571 14998865
36 Lenihan D. J. Alencar A. J. Yang D. Kurzrock R. Keating M. J. Duvic M. Cardiac toxicity of alemtuzumab in patients with mycosis fungoides/sézary syndrome Blood 2004 104 3 655 658 10.1182/blood-2003-07-2345 2-s2.0-3242816208 15073032
37 Attarian S. Wang C. Y. Romero J. Alemtuzumab induced ST-segment elevation and acute myocardial dysfunction Journal of Cardiology Cases 2014 10 5 176 179 10.1016/j.jccase.2014.07.004 2-s2.0-84908696357 30534236
38 Ahrabian D. Neill L. Bell R. Leary S. M. Acute cardiotoxicity associated with alemtuzumab infusion for multiple sclerosis Multiple Sclerosis Journal 2020 26 6 735 737 10.1177/1352458519855725 32298216
39 Hopfinger G. Busch R. Pflug N. Sequential chemoimmunotherapy of fludarabine, mitoxantrone, and cyclophosphamide induction followed by alemtuzumab consolidation is effective in T-cell prolymphocytic leukemia: FMC plus alemtuzumab in T-PLL Cancer 2013 119 12 2258 2267 10.1002/cncr.27972 2-s2.0-84878573270 23512246
40 Pallasch C. P. Leskov I. Braun C. J. Sensitizing protective tumor microenvironments to antibody-mediated therapy Cell 2014 156 3 590 602 10.1016/j.cell.2013.12.041 2-s2.0-84893502903 24485462
